tirzepatide and perimenopause Postmenopausal women on the GLP-1 medication (Zepbound) for obesity lost more weight if they were also using menopause hormone therapy, a retrospective cohort study indicated. https://www.medpagetoday.com/endocrinology/menopause/119594 Understanding the Impact of Tirzepatide

Retatrutide demonstrated significant improvements in body weight and metabolic outcomes among adults with obesity and had an appropriate safety profile

Over 18 months, participants were divided into two groups half received the active medication while the other half received placebo treatment

When just one medication isnt sufficient to treat diabetes, patients can take metformin and semaglutide together, explains Rekha Kumar, MD, MS, head of medical affairs at Found Health

1 October 2024

Eli Lilly has submitted regulatory inquiries and is expected to file a biologics license application (BLA) following Phase 3 completion